SEC Form 4 · accession 0000899243-17-016603
Dicerna Pharmaceuticals Inc · DRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ralf Rosskamp
Officer — Chief Medical Officer
Period of report
Jun 15, 2017
Accepted (ET)
Jun 16, 2017 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001399529
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $2.91 | Jun 15, 2017 | A | 250,000 | A | — | Jun 15, 2027 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The option vests 25% on the first year anniversary of the vesting start date of June 15, 2017 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the reporting person's continued employment with the issuer through the applicable vesting date.